MTM

Foundation Health Secures $6 Million in Seed Funding to Power the Next Generation of Consumer Healthcare Experiences

Retrieved on: 
Monday, March 11, 2024

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Foundation Health, a pioneering healthcare technology company, today announced the closure of a $6 million seed funding round.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Foundation Health, a pioneering healthcare technology company, today announced the closure of a $6 million seed funding round.
  • Foundation Health is dedicated to redefining the consumer healthcare experience by empowering clients to quickly develop and launch modern, digital-first pharmacy and telehealth solutions at scale.
  • "Our vision is to grow Foundation Health into the definitive tech platform for powering and managing complex consumer healthcare operations globally," said Foundation Health founder and CEO, Umar Afridi.
  • For more information about Foundation Health and its healthcare solutions, visit www.foundationhealth.com .

Outcomes Honors Achievements in Pharmacy Operations and Clinical Excellence at 2024 SYNC Outcomes National Conference

Retrieved on: 
Wednesday, March 6, 2024

In its inaugural year, the Outcomes SYNC National Conference brought together hundreds of leaders from world-class retail and chain pharmacies—as well as health plans and other stakeholders—to share best practices and help stakeholders strategically position for current and future challenges and opportunities.

Key Points: 
  • In its inaugural year, the Outcomes SYNC National Conference brought together hundreds of leaders from world-class retail and chain pharmacies—as well as health plans and other stakeholders—to share best practices and help stakeholders strategically position for current and future challenges and opportunities.
  • “From changes with direct and indirect remuneration (DIR) fees to the expansion of Medicare Advantage MTM eligibility, pharmacies and their healthcare stakeholder partners face significant changes in 2024 and need partners to help navigate coming challenges.
  • Outcomes is the only solutions company bringing pharmacies, payers and pharmaceutical manufacturers together to solve big problems,” says Jude Dieterman, Chief Executive Officer of Outcomes.
  • “These award winners have dedicated time and effort into transforming their businesses and operations in a forward-looking way.

Friedman Industries, Incorporated Announces Third Quarter Results

Retrieved on: 
Wednesday, February 14, 2024

Tubular product segment sales for the 2023 quarter totaled approximately $9.5 million compared to approximately $11.6 million for the 2022 quarter.

Key Points: 
  • Tubular product segment sales for the 2023 quarter totaled approximately $9.5 million compared to approximately $11.6 million for the 2022 quarter.
  • The average per ton selling price decreased from approximately $1,648 per ton in the 2022 quarter to approximately $1,164 per ton in the 2023 quarter.
  • Tons sold increased from approximately 7,000 tons in the 2022 quarter to approximately 8,000 tons in the 2023 quarter.
  • Sales volume for the fourth quarter of fiscal 2024 is expected to be slightly higher than the third quarter volume.

Primerica Reports Fourth Quarter 2023 Results

Retrieved on: 
Tuesday, February 13, 2024

Productivity, as measured by the number of policies issued per life-licensed reps per month, increased from an adjusted 0.20 policies in the fourth quarter of 2022 to 0.21 policies in the fourth quarter of 2023.

Key Points: 
  • Productivity, as measured by the number of policies issued per life-licensed reps per month, increased from an adjusted 0.20 policies in the fourth quarter of 2022 to 0.21 policies in the fourth quarter of 2023.
  • The fourth quarter results reflect lower sales from a less tenured agent mix.
  • During the fourth quarter of 2023, the segment recorded an adjusted operating pre-tax loss of $5.4 million compared to an adjusted operating pre-tax loss of $8.8 million in the fourth quarter of 2022.
  • The effective tax rate was 22.9% in the fourth quarter of 2023 compared to 21.4% in the prior year period.

Global Machine Tool Measurement Markets, 2022-2028 with 2023 as the Base year: Revenues, Revenue Projections, Average Pricing, and Market Concentration - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 1, 2024

The "Global Machine Tool Measurement Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Machine Tool Measurement Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research service offers a detailed analysis of the machine tool measurement (MTM) market.
  • The MTM market is mature, with machine tool original equipment manufacturers (OEMs) contributing to a large portion of the demand.
  • Annual estimates and forecasts, including revenues, revenue projections, average pricing, and market concentration, are provided for 2022 through 2028.

Ermenegildo Zegna Group Ends Full Year 2023 on a Strong Note With Accelerated Growth in the Fourth Quarter

Retrieved on: 
Wednesday, January 31, 2024

Ermenegildo “Gildo” Zegna, Chairman and CEO of the Zegna Group, said: “I am very proud of the Group’s success over the past year, which is demonstrated by our strong and continued revenues growth.

Key Points: 
  • Ermenegildo “Gildo” Zegna, Chairman and CEO of the Zegna Group, said: “I am very proud of the Group’s success over the past year, which is demonstrated by our strong and continued revenues growth.
  • For the full year 2023, Zegna Group generated revenues of €1,905 million, an increase of 27.6% year-over-year.
  • In the fourth quarter of 2023, the Group generated revenues of €570 million, an increase of 40.1% year-over-year.
  • Revenues growth in the fourth quarter of 2023 accelerated from the 20.8% year-over-year growth reported in the third quarter of 2023 (on a constant currency basis, revenues growth was 25.0% in the third quarter, with an organic growth rate of 11.3% for the same period).

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

Retrieved on: 
Thursday, January 18, 2024

Natera and its collaborators will present 11 abstracts that feature new Signatera data across various GI indications, including two oral presentations.

Key Points: 
  • Natera and its collaborators will present 11 abstracts that feature new Signatera data across various GI indications, including two oral presentations.
  • GALAXY is one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC).
  • Additionally, the first read-out from the Natera-sponsored BESPOKE CRC study will be presented in a rapid oral presentation.
  • BESPOKE CRC is the first large, prospective, US-based study in resectable CRC, with over 130 participating sites.

CONSORTIUM HEALTH PLANS APPOINTS NEW PRESIDENT AND CEO

Retrieved on: 
Tuesday, January 16, 2024

COLUMBIA, Md., Jan. 16, 2024 /PRNewswire/ -- Consortium Health Plans' Board of Directors has announced the appointment of Dave Busch as President and Chief Executive Officer. Busch will assume this role Tuesday, January 16. He succeeds Molly Loftus, who effectively retired at the end of 2023.

Key Points: 
  • COLUMBIA, Md., Jan. 16, 2024 /PRNewswire/ -- Consortium Health Plans' Board of Directors has announced the appointment of Dave Busch as President and Chief Executive Officer.
  • Busch joins Consortium from MTM, where he served as Chief Growth Officer, providing leadership for the sales and business development functions.
  • Kevin Cassidy, chairman of the board of Consortium, and President of National Accounts at Health Care Service Corporation said, "Dave's diverse and relevant leadership experience has prepared him for this unique opportunity to join the talented leaders at Consortium Health Plans and lead the Consortium through the complex and dynamic environment ahead of us."
  • Under Busch's leadership, Consortium will continue to support Blue Cross and Blue Shield teams to enable success in the National Account market.

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

Retrieved on: 
Thursday, December 21, 2023

To date, mVAF and MTM/mL are the two main metrics that have been used to quantify ctDNA levels in the blood.

Key Points: 
  • To date, mVAF and MTM/mL are the two main metrics that have been used to quantify ctDNA levels in the blood.
  • The premise is that MTM/mL is therefore more representative of a patient’s true disease burden, a hypothesis that was validated in this study.
  • Among the 18,426 patients with longitudinal ctDNA measurements, 13.3% had discordant ctDNA trajectories (increase/decrease) when calculated using MTM/mL versus mVAF.
  • As the only MRD test that uses MTM/mL, this study supports the utility of Signatera for ctDNA quantification, to measure treatment response at critical time points and inform decisions on how patients are managed.”

FedEx Reports Higher Second Quarter Diluted EPS of $3.55 and Adjusted Diluted EPS of $3.99

Retrieved on: 
Tuesday, December 19, 2023

The year-to-date decrease in outstanding shares benefited second quarter results by $0.05 per diluted share.

Key Points: 
  • The year-to-date decrease in outstanding shares benefited second quarter results by $0.05 per diluted share.
  • FedEx expects to repurchase an additional $1.0 billion of common stock during fiscal 2024.
  • We have supplemented the reporting of our financial information determined in accordance with GAAP with certain non-GAAP (or “adjusted”) financial measures, including our adjusted second quarter fiscal 2024 and 2023 consolidated operating income and margin, net income and diluted earnings per share, adjusted second quarter fiscal 2024 FedEx Express and FedEx Ground segment operating income and margin and adjusted second quarter fiscal 2023 FedEx Express segment operating income and margin.
  • We incurred costs associated with our business optimization initiatives in the second quarter of fiscal 2024 and fiscal 2023.